NASDAQ:SLGL

Sol-Gel Technologies Q2 2025 Earnings Results & Report

Sol-Gel Technologies logo
$52.83 -2.13 (-3.88%)
Closing price 04:00 PM Eastern
Extended Trading
$52.56 -0.27 (-0.51%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sol-Gel Technologies beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 15, 2025. The company reported EPS of $4.17 versus the -$0.67 consensus estimate, while revenue of $17.26 million topped the $2.86 million estimate by $14.40 million.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
6:00 PM ET

Sol-Gel Technologies EPS Results

Actual EPS
$4.17
Consensus EPS
-$0.67
Beat/Miss
Beat by +$4.84
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Sol-Gel Technologies Revenue Results

Actual Revenue
$17.26 million
Expected Revenue
$2.86 million
Beat/Miss
Beat by +$14.40 million
YoY Revenue Growth
N/A

Earnings Documents

Sol-Gel Technologies Q2 2025 Earnings FAQ

Sol-Gel Technologies (NASDAQ:SLGL) reported earnings of $4.17 per share for Q2 2025, beating the consensus estimate of -$0.67. The report was announced on Friday, August 15, 2025.

Sol-Gel Technologies reported revenue of $17.26 million for Q2 2025, against a consensus estimate of $2.86 million.

Sol-Gel Technologies Earnings Headlines

Contrasting Sol-Gel Technologies (SLGL) & Its Rivals
The next convergence is here
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
Sol-Gel Technologies (SLGL) Projected to Release Earnings on Thursday
See More Sol-Gel Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sol-Gel Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sol-Gel Technologies and other key companies, straight to your email.

About Sol-Gel Technologies

Sol-Gel Technologies (NASDAQ:SLGL) is an Israel-based dermatology company that develops topical treatments for skin conditions. Its proprietary technology uses silica-based microencapsulation to formulate active ingredients for topical use.

The company’s products include Epsolay, a benzoyl peroxide cream approved in the United States for inflammatory lesions of rosacea, and Twyneo, a topical combination of tretinoin and benzoyl peroxide approved for acne vulgaris.

Sol-Gel has pursued commercialization and licensing opportunities in the United States and other markets. Its business also includes developing additional dermatology treatments using its formulation platform.

View Sol-Gel Technologies Profile